BTHCF - Algernon Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2030
-0.0334 (-14.13%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.2364
Open0.2281
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2030 - 0.2315
52 Week Range0.0722 - 0.3982
Volume92,673
Avg. Volume55,129
Market Cap8.888M
Beta (3Y Monthly)6.39
PE Ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Algernon Retains Renmark Financial Communications

    Algernon Pharmaceuticals Inc. (CSE:AGN) (AGW.F) (BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has retained the services of Renmark Financial Communications (“Renmark”) to help communicate the Algernon story and its unique value proposition to its well established retail broker network throughout the US and Canada. In consideration of the services to be provided, the Company will pay Renmark a monthly retainer of $7,000 CDN, for a period of 6 months ending on Sept 10th, 2019.

  • GlobeNewswire23 days ago

    Algernon Pharmaceuticals Expands Its Research Program to Include Idiopathic Pulmonary Fibrosis

    Algernon Pharmaceuticals Inc. (CSE:AGN) (AGW.F) (BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that based on positive preliminary data from its first idiopathic pulmonary fibrosis (IPF) study, the Company has decided to conduct further research on compound NP-251. Because fibrosis is a major underlying condition for many serious diseases, and as a result of the success of several Algernon compounds previously demonstrating anti-fibrotic activity in CKD and NASH, the Company screened a number of its lead compounds for IPF. Out of the 8 compounds screened by the Company during the early research phase, NP - 251 showed the most promise.

  • GlobeNewswirelast month

    Breathtec Announces Name Change to Algernon Pharmaceuticals

    New corporate identity aligned with the Company's main strategy to be a global leader in the treatment of liver disease (NASH), chronic kidney disease and inflammatory bowel disease. The company's ticker symbol will change to "AGN" on the Canadian Securities Exchange effective before market opens on Tuesday, February 19, 2018.

  • GlobeNewswirelast month

    Nash Pharmaceuticals to Present Data on Its Inflammatory Bowel Disease Research Program at The Digestive Disease Week Annual Conference

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that it has been accepted to present its pre-clinical data on its inflammatory bowel disease (“IBD”) research program for both Colitis and Crohn’s disease at the upcoming Digestive Disease Week Annual Conference, held in San Diego, CA on May 18th -21st.

  • GlobeNewswire2 months ago

    Nash Pharmaceuticals to Present Pre-Clinical Data on Non-Alcoholic Fatty Liver Disease at 2nd Global NASH Congress in London, UK

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (the “Company” or “Nash Pharma”) is pleased to announce that it will be presenting its pre-clinical data on its non-alcoholic steatohepatitis (“NASH”) research program at the upcoming Global NASH Congress, held in London, UK, February 25th & 26th, 2019. Results of a recently announced in vivo study, showed Nash Pharma’s lead compound NP-135 showed an 84.4% reduction in fibrosis. NP-135 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy.

  • GlobeNewswire2 months ago

    Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. In addition, a second compound, NP-135 was identified as an additional lead.

  • GlobeNewswire2 months ago

    Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease as well as 2 Additional Lead Targets

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that in a new recent in vivo animal study for Chronic Kidney Disease (CKD), the activity of NP-135 was confirmed, and two additional compounds, NP-160 and NP-251 were identified as new lead compounds in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis.

  • GlobeNewswire2 months ago

    Shareholder Press Release

    Breathtec Biomedical Inc. (BTH.CN) advises that Kulwant Malhi (the “Acquiror”), through a series of securities acquisition transactions in the share capital of Breathtec BioMedical Inc. (the “Issuer”), and immediately after these securities transactions, owns or controls directly and indirectly, an aggregate of 6,851,171 common shares (the “Shares”) of the Issuer, representing approximately 23.886% of the Issuer’s issued and outstanding Shares. The Acquiror acquired the Shares on the public market through the facilities of the Canadian Securities Exchange, by way of an offering by the Issuer and/or by way of a share exchange agreement (the share exchange as more particularly described in the Issuer’s October 22, 2018, October 9, 2018 and August 2, 2018 news releases).

  • GlobeNewswire4 months ago

    Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that in a recent in vivo animal study for Crohn’s disease (CD), NP-178, its lead compound for the treatment of ulcerative colitis (UC), performed equivalent to and in some measurements, better than 5-ASA, a current global standard of care treatment for inflammatory bowel disease (IBD). A new potential treatment for CD could lead to an orphan drug designation, which could help expedite its availability to patients. There are a number of countries globally, that have an orphan drug program in place whereby companies that develop drugs for certain rare diseases enjoy enhanced collaboration with the regulatory authority, incentives, marketing exclusivity, and improved pricing and reimbursement.

  • GlobeNewswire4 months ago

    Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that one of its lead compounds for Inflammatory Bowel Disease (“IBD”) NP-178 showed positive results in a recently completed study investigating its therapeutic effects in an ulcerative colitis mouse model. NP-178 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy.

  • GlobeNewswire5 months ago

    Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease

    Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. NP-160 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy.